

Mechanism of activation of clopidogrel into its active thiol metabolite: P450-catalyzed opening of the 2-oxo-clopidogrel thiolactone: S-oxidation or Baeyer-Villiger oxidation?

Patrick M Dansette, Daniel Mansuy

▶ To cite this version:

Patrick M Dansette, Daniel Mansuy. Mechanism of activation of clopidogrel into its active thiol metabolite: P450-catalyzed opening of the 2-oxo-clopidogrel thiolactone: S-oxidation or Baeyer-Villiger oxidation?. ISSX/DMDG 2023 Meeting, Jun 2023, Hertfordshire, United Kingdom. hal-04124161

HAL Id: hal-04124161 https://hal.science/hal-04124161

Submitted on 9 Jun2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Mechanism of activation of clopidogrel into its active thiol metabolite: P450-catalyzed opening of the 2-oxo-clopidogrel thiolactone : S-oxidation or Baever-Villiger oxidation?





) from dioxygen

Patrick M. Dansette and Daniel Mansuy, Université Paris Cité, LCBPT, CNRS UMR 8601, Paris

Introduction: Clopidogrel and ticlopidine are activated to the thiol active metabolite, that inhibits receptor P2Y12, in two oxidative steps and a reduction: First P450 catalysed oxidation into thiolactones : 2-oxo-clopidogrel and 2-oxo-ticlopidine. Second, P450-catalyzed opening into a **sulfenic acid** (1). We proposed that the thiolactone is oxidized to a **thiolactone S-oxide (Path A)** that hydrolyzes to a **sulfenic acid**, reacting with glutathione to give a mixed disulfide, further reduced (enzymatically or chemically) to the active thiol. Alternatively in presence of dimedone the sulfenic acid is trapped as a stable dimedone adduct (1, 2) or in presence of thiols into mixed disulfides that are reduced by excess thiol into the active thiol and its isomers (1). In presence of ascorbic acid, TCEP or DTT, the sulfenic acid is reduced into the active thiol (2).

A recent paper by Zhu (3) challenges our hypothesis and propose an alternative **Baeyer-Villiger oxidation** of the thiolactone **(Path B) th**rough a 3-oxo-1,2-oxathiolane, followed by nuceophilic attack by the heme-Fe-O⁻ (**Path C**) to afford the same **sulfenic acid intermediate**.





The acid group OH comes from water in Path A and B! It comes from dioxygen in Path B. In path C the Sulfenic OH comes from dioxygen

The aim of our study is to use as end product the **sulfenic acid dimedone adduct** to analyze incorporation of ¹⁸O from ¹⁸O water or ¹⁸O dioxygen, and compare it to the incorporation of ¹⁸O in other cometabolites in incubations of clopidogrel (and 2-oxo-clopidogrel and 2-oxo-ticlopidine) with rat liver microsomes (RLM), to try to decide between these two hypothical pathways. The ¹⁸O incorporation should be different for each pathway as shown in Scheme 1. Thus starting from clopidogrel the carbonyle (CO) of the thiolactone (2-oxoclopidogrel) and that of the dimedone adduct comes from dioxygen.


The OH of the carboxylic (COOH) group comes from water in Path A and B', from dioxygen Path B. In the hypothesis of Zhu (Path C) both the acid OH and the sulfenic OH come from dioxygen.


Methods : Clopidogrel, 2-oxoclopidogrel and 2-oxoticlopidine (100 μ M) were incubated with phenobarbital treated rat liver microsomes (1) in presence of 1mM NADPH and 1 mM dimedone, either in normal pH 7.4 phosphate buffer or in buffered ¹⁸O water or in presence of ¹⁸O dioxygen. After 30 min the reaction was stopped with half volume CH₃CN/AcOH 9/1 and centrifuged. The supernatant was analyzed by HPLC/MS (Thermo Surveyor and a LCQ advantage) as described (1) using MS and MS/MS.

Results : Clopidogrel was metabolized in addition to the dimedone adduct into a number of other metabolites as shown in Scheme 2 : 2-oxo-clopidogrel, 7a-hydroxy-2-oxo-clopidogrel, clopidogrel S-oxide dimer, clopidogrel sesquioxide and clopidogrel acid.

The results show that the oxygen atoms of the first oxidation for 2oxo-clopidogrel (thiolactone, one **O**), clopidogrel S-oxide dimer (two **O**) came from dioxygen. Clopidogrel sesquioxide, (oxidized dimer), incorporated **three O** atoms from dioxygen. **Two O** were incorporated into 7a-hydroxy-2-oxo-clopidogrel (one in the CO and one in the 7a-OH). Clopidogrel acid incorporated **O** from water. These metabolites Scheme 2 : Other microsomal metabolites of clopidogrel







ciopidogrei acid	11/2 - 300	m/2 = 310	+2), one0 nom water	111/2 = 300	(Liace +2)	
allow to verify the presen t in the inc		on conc	litions (if 18 0 w	ater or	dioxygen we	ere

m/z =

m/z = 69

m/z = 691

However the **dimedone adduct** derived from clopidogrel incorporated only one **O from dioxygen** in the **CO** of the COOH coming from its thiolactone precursor and only traces of a second oxygen. The **O**H of the COOH came from **water**.

Thus the above results agree with Path **A** or **B**'. The fact that **O**H of the carboxylic acid comes from **water** is not compatible with path **B** nor **C**.

However Path **B** and **C** is not totally excluded because of the slight incorporation of a second oxygen into the dimedone adduct (3-8%).

Similar results were obtained for 2-oxo-ticlopidine: The **7a-OH** of 7ahydroxy-2-oxo-ticlopidine came from ¹⁸O dioxygen. The carboxyle-OH of the dimedone adduct came from ¹⁸O water and not from dioxygen.

Also 2-oxo-prasugrel gave similar results (4).

Discussion : The results obtained show that only **Path A** or **B'** are compatible with the oxygen incorporation found. The slight ¹⁸O incorporation from dioxygen into the dimedone adducts (< 8%) could be due to some exchange or to **Path C** proposed by Pr Zhu. Thus a Baeyer-Villiger oxidation cannot be fully excluded. Path **A** and **B'** (nucleophilic attack at CO) is also compatible with the fact that the reactive intermediate acts as a bis-electrophile (5). Path **B** and **C** are not!

Diels-Alder adducts with dienophiles of 2-hydroxy-thiophene S-oxides, tautomer of the thiolactone sulfoxides, support **Path A** (7).

Analogous reactive intermediates, a thiolactone Sulfoxide or a 3oxo-1,2-oxathiolane (a carboxylic-sulfenic anhydride), were proposed by Latham and Walsh in the inactivation by thiolactones of a Baeyer-Villiger flavo-protein : cyclohexanone mono-oxygenase (6).

References:

1) Dansette P.M., Libraire J., Bertho G. and Mansuy D.. Metabolic oxidative cleavage of thioesters: evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel Chem. Res. Toxicol. (2009) 22, 369. 2) Mansuy D. and Dansette P.M., Sulfenic acids as reactive intermediates in xenobiotic metabolism. Arch. Biochem. Biophys. (2011) 507, 174. 3) Zhu Y., Zhou J. and Romero E.L., Reinvestigation of clopidogrel bioactivation unveils new cytochrome P450-catalyzed thioester cleavage mechanism. Bioorg. Med. Chem. Lett. 72 (2022) 128872. 4) Dansette P.M., Thebault S., Bertho G. and Mansuy D. Formation and fate of a sulfenic acid intermediate in the metabolic activation of the antithrombotic prodrug prasugrel. Chem. Res. Toxicol. (2010) 23, 1268–1274. 5) Dansette P.M., Levent D., Hessani A. and Mansuy D. Thiolactone sulfoxides as new reactive metabolites acting as bis-electrophiles: implication in clopidogrel and prasugrel. Chem Res Toxicol. 2013 May 20;26(5):794-802. 6) Latham J.A. and Walsh C.T. Mechanism-Based Inactivation of the Flavoenzyme Cyclohexanone Oxygenation of Cyclic ThiolEster Substrates. J. Am. Chem. Soc. 1987, 109, 3421-3427. 7) Dansette P. Other poster at ISSX/DMDG.